文章基本信息

标题：Efficacyandsafety of Elagolix in the treatment of endometriosis associated pain: a systematic reviewandnetwork meta-analysis
本地全文：下载
作者：Omar M Mattar ; Lubaba O Namous ; Mohamed Ros 等
期刊名称：Proceedings in Obstetrics and Gynecology
印刷版ISSN：2154-4751
出版年度：2021
卷号：10
期号：2
页码：1-13
DOI：10.17077/2154-4751.1510
语种：English
出版社：University of Iowa
摘要：Endometriosis commonly presents with dysmenorrhea, non-menstrual pelvic pain,andinfertility. Elagolix is an oral, short-acting, gonadotropin-releasing hormone antagonist acting through complete estrogen suppression. Objective: To evaluate the evidence from published randomized controlled trials (RCTs) about the efficacyandsafety of Elagolix in the treatment of endometriosis associated pain. Search strategy: Electronic databases containing articles published between January 2000andFebruary 2020 were searched using the MeSH terms (Elagolix OR gonadotropin-releasing hormone antagonist OR GnRH antagonist OR antigonadotropin)and(endometriosis)and(pelvic pain). Selection criteria: All RCTs assessing the efficacy of Elagolix in the treatment of pain associated with endometriosis were considered for this network meta-analysis, where five studies were deemed eligible for this review. Data collectionandanalysis: The mean difference (MD)andconfidence intervals (95% CI) for continuous outcomes including analgesic use, dysmenorrhea, non-menstrual pelvic pain,andquality of life were calculated. Main results: Elagolix 250 mg reduced dysmenorrhea significantly, as compared to placebo, (MD = -0.41, 95% CI [-0.7, -0.13]) at 12 weeks, while Elagolix 200 mg reduced dysmenorrhea significantly (MD= -1.2, 95% CI [-1.9, -0.57]) compared to placebo after 24 weeks of treatment. Conclusions: Elagolix 200 mg seems to be an effective drug with fewer side effects when used to reduce dysmenorrheaandnon-menstrual pelvic pain after 24 weeks of treatment in patients with endometriosis.
关键词：Endometriosis;Elagolix;GnRH antagonist;pain;dysmenorrhea